The time is different now in terms of winning approval for new drugs to treat obesity, says Saniona CEO Jørgen Drejer. The international community has admitted that we are in the midst of an epidemic, he believes.
Lundbeck has published fresh data on its candidate drug desmoteplase, which failed a phase III study during the summer. The company has yet to decide on whether or not to shelve the candidate - a decision that could ultimately cost it more than USD 50 million.
A US District Attorney is examining possible manufacturing issues at Novo Nordisk’s plant in Kalundborg. The move has caught the Danish diabetes giant off guard, although it is the second time the group has been targeted by the same DA.
According to research firm Bernstein, Danish manufacturers William Demant and GN Store Nord are among the contenders for Siemens’ hearing devices unit. The firm also explains why a deal would not conflict with antitrust rules.
Founder, major shareholder and former Chairman in Bavarian Nordic, Asger Aamund, calls it a “happy day”, although Wednesday’s licensing pact with J&J was expected. And he admits that it gives him a sense of satisfaction to see so many people be wrong about the Danish biotech company.
The battle for Coloplast rival Smith & Nephew will be fought between two players with very different reasons for taking an interest in the company, says research firm Bernstein. But Smith & Nephew is fighting to remain independent.
Having tried to conquer market shares in the US for years with no luck, Danish medtech group Radiometer has now been forced to make a change: Employees are being let go by the numbers and the company’s US headquarters have been moved.
The replacement for Torbjørn Bjerke has been found two weeks after the Danish CEO was fired by Sweden’s Karolinska Development. The new chief has previously founded a biotech company that was sold to Merck in a billion-dollar deal recently.
Swiss-based hearing devices manufacturer Sonova launched a new product platform this Tuesday, but the launch is bound to disappoint on one crucial point, to the benefit of Denmark’s GN Resound, says research firm Bernstein.
The desired investor base and pricing are factors that determine a company’s choice of stock exchange, says the head of EY Life Science, who expects to see IPOs of Danish biotech companies this year. But there is a catch.
MedWatch has delved into the books and analyzed how the major players in the Danish pharmaceutical industry perform. Unsurprisingly, Novo Nordisk ranks high in the Danish hierarchy, but it’s a foreign company that tops the list.
Novo Nordisk already has a solid pipeline of obesity drugs, but the launch of a new research center in Seattle should further accelerate early stage R&D in the field - and there is a very clear reason the US city was chosen as the site, says the group's CSO.
Camilla Harder Hartvig has moved from senior positions with Novartis and AstraZeneca to becoming the head of Allergan’s Nordic business - and the task of having to interact with healthcare bodies on behalf of her new company presents brand new challenges.
An employee’s level of commitment can be affected by circumstances in the family, such as disease – and the company should be sensitive to that. But if people are down-right uncommitted, the corporate culture is so strong that it will gradually expel them. Lars Rebien, at the peak of his career, spoke to Medwatch about the unique Novo spirit, about failing politicians, and about growing softer.
Gitte Pedersen’s career began in Novo Nordisk and the Danish drug giant led her to the US, where she is now CEO and co-founder of a diagnostics company in Manhattan – a career that is partly formed by a past peopled by engineers and women’s rights activists.